Zenocutuzumab--zbco, marketed as BIZENGRI (R), received Breakthrough Therapy Designation from the FDA in October 2025 and was granted accelerated approval in December 2024 for adults with advanced ...

Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary ...

Na’ama Avitzur, MD, is a pulmonologist and a fellow at the University of British Columbia, researching interstitial lung disease and an internal medicine physician. A European Respiratory Journal ...

In fibrotic ILD, desaturation recovery post 6MWT is linked to disease progression, baseline disease severity, and transplant-free survival.

The sBLA is supported by results from the pivotal phase 3 TROPION-Breast02 clinical trial (NCT05374512), which evaluated the ...

In this Q&A, Avitzur breaks down the study’s findings and suggests how the information can be used to advance PF research and treatments. This transcript has been lightly edited for clarity. AJMC: ...

Traction bronchiectasis on computed tomography and body mass index were significantly associated with PPF, while radiological and symptomatic progression and older age were significantly associated ...

The Union Budget had room for cancer care, mental health, biopharma, and even wellness narratives. But in a country choking ...

Following three-year-old Mavericks's diagnosis of an interstitial lung disease, also known for its acronym NEHI, Maverick's ...

Research suggests that it is important for clinicians to identify the risk for ILD in patients with SSc so that therapy can be initiated.

A novel recovery index (RI) integrates desaturation degree, recovery time, and supplemental oxygen use, offering prognostic ...

Only about 150 to 200 lung transplants are carried out in the UK each year and it can be hard to find a suitable donor ...